Related Experiment Video
Updated: Nov 3, 2025

Intracranial Pharmacotherapy and Pain Assays in Rodents
Published on: April 9, 2019
Emerging Role of Serum Glucocorticoid-Regulated Kinase 1 in Pathological Pain
Baowen Liu1, Ningbo Li1, Zhigang He2
1Department of Anesthesiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Abstract:
Currently, the management of acute and chronic pain in clinical practice remains unsatisfactory due to the existence of limited effective treatments, and novel therapeutic strategies for pathological pain are urgently needed. In the past few decades, the role of serum and glucocorticoid-inducible kinase 1 (SGK1) in the development of pain and diurnal rhythms has been implicated in numerous studies. The expression levels of SGK1 mRNA and protein were found to be elevated in the spinal cord and brain in various pathological pain models. Blocking SGK1 significantly attenuated pain-like responses and the development of pathological pain. These studies provide strong evidence that SGK1 plays a role in the development of various types of pathological pain and that targeting SGK1 may be a novel therapeutic strategy for pain management. In this review article, we provide evidence from animal models for the potential role of SGK1 in the regulation of pathological pain caused by inflammation, nerve injury, psychiatric disorders, and chronic opioid exposure.
Related Concept Videos
The JAK-STAT Signaling Pathway
MAPK Signaling Cascades
NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The...
Nociception
cAMP-dependent Protein Kinase Pathways
GPCRs Regulate Adenylyl Cylase Activity

